Covid-19 roundup: EMA starts review of SK’s vaccine; Australian biotech switching gears away from Covid research
Another Covid-19 vaccine will enter the fray as the EMA kicks off its conditional marketing authorization application for SK’s vaccine, dubbed Skycovion.
SK Chemicals GmbH submitted data to the EMA on how well the vaccine triggers the production of antibodies against the original strain of SARS-CoV-2, along with data on the safety and quality of the vaccine.
“The evaluation of Skycovion is one of the ongoing evaluations of data on Covid-19 vaccines. As the pandemic continues to evolve, it is important that the EU has a wide array of vaccines and treatments to enable the Member States to combat the pandemic effectively. EMA and its scientific committees are committed to ensuring a robust review of all data on COVID-19 vaccines and medicines,” the EMA said in a statement.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.